Gold stocks to beat market volatility
Gold stocks to beat market volatility
Prescient’s “BASKET” Approach Transforming Future Clinical Trials

Prescient’s “BASKET” Approach Transforming Future Clinical Trials

  • Jan 30, 2020 AEDT
  • Team Kalkine

Clinical-stage oncology company, headquartered in Melbourne, Australia, Prescient Therapeutics (ASX:PTX) (“Prescient”), develops personalised medicines to defeat cancer taking an approach to address mutations that cause cancer. Current &...

Prescient Therapeutics' Remarkable 2019 Journey

Prescient Therapeutics' Remarkable 2019 Journey

  • Jan 03, 2020 AEDT
  • Team Kalkine

A clinical-stage Oncology company, Prescient Therapeutics Limited (ASX: PTX) is primarily engaged in developing novel personalized cancer therapies targeting an array of challenging cancers with significant unmet need. Prescient’s approach...

Another Feather in Prescient’s Hat, Promising Efficacy Results from PTX-200 Phase 2a trial in HER2-Negative Breast Cancer

Another Feather in Prescient’s Hat, Promising Efficacy Results from PTX-200 Phase 2a trial in HER2-Negative Breast Cancer

  • Dec 24, 2019 AEDT
  • Team Kalkine

Of late, clinical stage oncology company, Prescient Therapeutics (ASX: PTX), focused on developing personalized medicines with an approach to address mutations causing cancer, has been under the spotlight for recent advancements in its clinical trial...

Prescient Takes Another Leap Forward, Unveils Promising Interim Results from PTX-200 Phase 1b Ovarian Cancer Trial

Prescient Takes Another Leap Forward, Unveils Promising Interim Results from PTX-200 Phase 1b Ovarian Cancer Trial

  • Dec 18, 2019 AEDT
  • Team Kalkine

Clinical stage oncology company engaged in developing personalised medicine approaches including targeted and cellular therapies to beat cancer, Prescient Therapeutics (ASX: PTX) has been gaining industry limelight for its advancing clinical trials. ...

Prescient Collaborates with Carina Biotech in Expansion into Exciting CAR-T Therapies

Prescient Collaborates with Carina Biotech in Expansion into Exciting CAR-T Therapies

  • Dec 10, 2019 AEDT
  • Team Kalkine

Prescient Therapeutics Limited (ASX: PTX) develops personalised medicine approaches to address mutations that cause cancer. The Company employs a targeted therapy approach to target individual tumour variability rather than the conventional one size ...

Prescient Unveils Encouraging Results: Eradication of Cancer in Three Acute Myeloid Leukemia Patients

Prescient Unveils Encouraging Results: Eradication of Cancer in Three Acute Myeloid Leukemia Patients

  • Nov 28, 2019 AEDT
  • Team Kalkine

Clinical-stage Oncology Company, Prescient Therapeutics Limited (ASX: PTX), that develops personalised medicine approaches to address mutations causing cancer. Prescient?s deep product pipeline include 2 clinical stage drugs with multiple shots on go...

A Walk-Through Prescient’s 2019 Achievements

A Walk-Through Prescient’s 2019 Achievements

  • Nov 25, 2019 AEDT
  • Team Kalkine

Prescient Therapeutics Limited (ASX:?PTX) is involved in the development of breakthrough personalised cancer therapies via its novel anti-cancer drug candidates, PTX-100 and PTX-200, that have shown great promise in the treatment of a range of debili...

Prescient Therapeutics Collaborates with Carina Biotech for Development of Next Generation CAR-T Therapies

Prescient Therapeutics Collaborates with Carina Biotech for Development of Next Generation CAR-T Therapies

  • Nov 19, 2019 AEDT
  • Team Kalkine

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug development focused on new cancer drugs. The company is known for having a robust clinical pipeline with two drug candidates, PTX ...

Shedding light on the Recent Fuss about RAS, Prescient released AusBiotech Presentation

Shedding light on the Recent Fuss about RAS, Prescient released AusBiotech Presentation

  • Nov 11, 2019 AEDT
  • Team Kalkine

With a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX:?PTX) develops personalised medicines as potential novel cancer remedies targeting an array of debilitating cancers with significant unmet need. ?Prescient has a...

Prescient’s September 2019 Quarterly Update Unveils Encouraging Developments

Prescient’s September 2019 Quarterly Update Unveils Encouraging Developments

  • Nov 06, 2019 AEDT
  • Team Kalkine

Prescient Therapeutics Limited (ASX:?PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel targeted cancer therapies for a range of challenging cancers with significant unmet need. Prescient?s appro...

Register Now

Get a call back now to get stock recommendations

x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK